MK-801-induced hyperlocomotion: Differential effects of m100907, SDZ PSD 958 and raclopride

European Journal of Pharmacology

Volumn 335, Issue 2-3, 1997, Pages 107-116

  Martin, Peter ^a   Waters, Nicholas R ^a   Waters, Susanna E ^a   Carlsson, Arvid ^a   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Dopamine receptor antagonist; Locomotion; M100907 (R(+) (2,3 dimethoxyphenyl) 1 2(4 fluorophenyl)ethyl) 4 piperidine methanol, MDL100,907); MK 801 ( + 5 methyl 10,11 dihydro 5H dibenzo a,d cyclohepten 5,10 imine hydrogen maleate, dizocilpine); Mouse; Schizophrenia

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DIZOCILPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RACLOPRIDE; SDZ PSD 958; SEROTONIN 2 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; MULTIPLE REGRESSION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FLUOROBENZENES; HYPERKINESIS; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; QUINOXALINES; RACLOPRIDE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SALICYLAMIDES; SEROTONIN ANTAGONISTS;

EID: 0030754797     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01188-6     Document Type: Article

References (41)

1. Altman, D.G., 1991. Practical Statistics for Medical Research. Chapman and Hall, London, pp. 611.
2. 2) receptors. Eur. J. Pharmacol. 129:1986;367-370.
3. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
4. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
5. 2A-receptor antagonist MDL100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - Implications for psychosis. J. Neural. Transm. Gen. Sect. 100:1995;225-237.
6. Christensen A.V., Arnt J., Hyttel J., Larsen J.J., Svendsen O. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci. 34:1984;1529-1540.
7. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. Central Sympathomimetic Activity of (+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug. Dev. Res. 2:1982;135-145.
8. Dall'Olio R., Gandolfi O., Montanaro N. Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacol. Berl. 107:1992;591-594.
9. Doehlert, D.H., 1970. Uniform shell designs. In: Applied Statistics, vol. 19, pp. 231-239.
10. 2a-Receptor Antagonist. Society for Neuroscience, St. Louis, Abstr. 427.19.
11. 2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J. Pharmacol. Exp. Ther. 261:1992;1273-1281.
12. Hiramatsu M., Cho A.K., Nabeshima T. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol. 166:1989;359-366.
13. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. Gen. Sect. 89:1992;1-10.
14. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
15. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., Korduba C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 226:1983;462-468.
16. Jackson D.M., Westlind Danielsson A. Dopamine receptors: Molecular biology, biochemistry and behavioural aspects. Pharmacol. Ther. 64(2):1994;291-370.
17. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatr. 9:1987;12-35.
18. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatr. 148:1991;1301-1308.
19. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277:1996;968-981.
20. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
21. Kornhuber J., Kornhuber M.E. Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci. 39:1986;674-699.
22. Köhler C., Hall H., Ögren S.-O., Gawell L. Specific in vitro and in vivo binding of 3H-raclopride - A potent substituted benzamide drug with high affinity for dopamine D-2 receptors. Biochem. Pharmacol. 34:1985;2251-2259.
23. Laruelle M., Abi Dargham A., Casanova M.F., Toti R., Weinberger D.R., Kleinman J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psychiatry. 50:1993;810-818.
24. 2 antagonist. Mol. Pharmacol. 27:1985;600-611.
25. Liljequist S., Ossowska K., Grabowska Anden M., Anden N.E. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur. J. Pharmacol. 195:1991;55-61.
26. Löscher W., Hönack D. The behavioural effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215:1992;199-208.
27. 2A receptor antagonist. Eur. J. Pharmacol. 259:1994;137-141.
28. Markstein R., Gull P., Rüedeberg C., Urwyler S., Jaton A.L., McAllister K., Dixon A.K., Hoyer D. SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity. J. Neural Transm. Gen. Sect. 103:1996;261-276.
29. Martin P., Svensson A., Carlsson A., Carlsson M.L. On the roles of dopamine D-1 versus D-2 receptors for the hyperactivity response elicited by MK-801. J. Neural Transm. Gen. Sect. 95:1994;113-121.
30. 2A receptors. Eur. J. Pharmacol. 280:1995;R9-11.
31. Meltzer H.Y. An overview of the mechanism of action of clozapine. J. Clin. Psychiatr. 55(Suppl. B):1994;47-52.
32. 2 receptors in the rat brain: Neurochemical identification of cell types by immunocytochemistry. Neuropsychopharmacology. 11:1994;157-166.
33. Ögren S.O., Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology. 11:1994;167-177.
34. 2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacol. Berl. 111:1993;427-434.
35. 2 binding sites both in vitro and in vivo. Eur. J. Pharmacol. 210:1992;279-284.
36. 2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
37. 2 receptor and alpha 1-adrenoceptor antagonism. J. Clin. Psychopharmacol. 15:1995;11s-18s. published erratum appears in J. Clin. Psychopharmacol. 15(2) (1995) 154.
38. Tiedtke P.I., Bischoff C., Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm. Gen. Sect. 81:1990;173-182.
39. Tricklebank M.D., Singh L., Oles R.J., Preston C., Iversen S.D. The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 167:1989;127-135.
40. Waters, E.S., Waters, N., Hansson, L., Carlsson, M.L., 1995. Interactions between Central Glutamatergic, Dopaminergic and Serotonergic Neurotransmission in the Control of Locomotor Activity. Society for Neuroscience, San Diego, Abstr. 153.13.
41. Wong E.H., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc. Natl. Acad. Sci. USA. 83:1986;7104-7108.